JP2019521312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521312A5 JP2019521312A5 JP2018554537A JP2018554537A JP2019521312A5 JP 2019521312 A5 JP2019521312 A5 JP 2019521312A5 JP 2018554537 A JP2018554537 A JP 2018554537A JP 2018554537 A JP2018554537 A JP 2018554537A JP 2019521312 A5 JP2019521312 A5 JP 2019521312A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- clever
- patient
- tnf
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000028327 secretion Effects 0.000 claims 4
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 210000004322 M2 macrophage Anatomy 0.000 claims 2
- 101700006809 STAB1 Proteins 0.000 claims 2
- 102100013396 STAB1 Human genes 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 210000003690 classically activated macrophage Anatomy 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000001616 Monocytes Anatomy 0.000 claims 1
- 101000212627 STAB1 Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 102000031486 human STAB1 protein Human genes 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (3)
- ヒトCLEVER−1のエピトープに結合することのできる抗体またはその断片を患者に投与した場合の、前記患者における抗−CLEVER−1治療の有効性の評価方法であって、前記抗体またはその断片が、エピトープ配列:
PFTVLVPSVSSFSSR(配列番号1)および
QEITVTFNQFTK(配列番号2)
に結合し、
(a)前記患者から採取された血液試料から末梢血単球(PBLs)を得る工程、
(b)前記PBLsのTNF−アルファ分泌を測定する、および/またはCD14陽性PBLs上のHLA−DR発現を測定する工程、および
(c)工程(b)で測定されたTNF−アルファ分泌および/またはHLA−DR発現の値を、抗−CLEVER−1治療の有効性を評価するために対照値と比較する工程であって、対照値が、患者においてCLEVER−1に結合することのできる抗体またはその断片を投与する前に測定された値、または同じ患者において異なる時点で行われた1つ以上の先の測定値であり、TNF−アルファ分泌またはHLA−DR発現の増加がM2マクロファージのM1マクロファージへの変化および抗−CLEVER−1治療の有効性を示す工程
を含む方法。 - エピトープが、さらに
ATQTGRVFLQ(配列番号:3)、
DSLRDGRLIYLF(配列番号:4)、
SKGRILTMANQVL(配列番号:5)、および
LCVYQKPGQAFCTCR(配列番号:6)
からなる群より選択される1つ以上の配列を含む
請求項1記載の方法。 - 対照値と比較した測定されたTNF−アルファ分泌の少なくとも2倍の増加が、M2マクロファージのM1マクロファージへの変化を示す請求項1または2記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022020859A JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Clever-1、tnf-アルファおよびhla-dr結合剤を用いた免疫活性化の診断 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20165336 | 2016-04-18 | ||
FI20165336 | 2016-04-18 | ||
PCT/FI2017/050286 WO2017182706A1 (en) | 2016-04-18 | 2017-04-18 | Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022020859A Division JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Clever-1、tnf-アルファおよびhla-dr結合剤を用いた免疫活性化の診断 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019521312A JP2019521312A (ja) | 2019-07-25 |
JP2019521312A5 true JP2019521312A5 (ja) | 2020-03-05 |
JP7100588B2 JP7100588B2 (ja) | 2022-07-13 |
Family
ID=58692521
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018554537A Active JP7100588B2 (ja) | 2016-04-18 | 2017-04-18 | Clever-1、tnf-アルファおよびhla-dr結合剤を用いた免疫活性化の診断 |
JP2022020859A Active JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Clever-1、tnf-アルファおよびhla-dr結合剤を用いた免疫活性化の診断 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022020859A Active JP7302049B2 (ja) | 2016-04-18 | 2022-02-14 | Clever-1、tnf-アルファおよびhla-dr結合剤を用いた免疫活性化の診断 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10884000B2 (ja) |
EP (1) | EP3445786B1 (ja) |
JP (2) | JP7100588B2 (ja) |
KR (1) | KR102403660B1 (ja) |
CN (1) | CN109153720B (ja) |
AU (1) | AU2017252344B2 (ja) |
BR (1) | BR112018070350A2 (ja) |
CA (1) | CA3020418A1 (ja) |
EA (1) | EA201892313A1 (ja) |
WO (1) | WO2017182706A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020089531A1 (en) | 2018-11-01 | 2020-05-07 | Faron Pharmaceuticals Oy | Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages |
EP4058805A1 (en) * | 2019-11-11 | 2022-09-21 | Faron Pharmaceuticals OY | Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment |
CA3174858A1 (en) * | 2020-04-20 | 2021-10-28 | Juho JALKANEN | Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor |
US20220227858A1 (en) | 2021-01-18 | 2022-07-21 | Faron Pharmaceuticals Oy | Controlling of immune activation by soluble clever-1 |
WO2023105118A1 (en) * | 2021-12-07 | 2023-06-15 | Faron Pharmaceuticals Oy | Method for using inflammatory markers to guide anti-clever-1 cancer treatment |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE372348T1 (de) | 2002-01-09 | 2007-09-15 | Faron Pharmaceuticals Oy | Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung |
FI20090161A0 (fi) | 2009-04-22 | 2009-04-22 | Faron Pharmaceuticals Oy | Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä |
SG11201502827RA (en) | 2012-11-09 | 2015-05-28 | Transgene Sa | Modulation of monocytes, or precursors thereof, differentiation |
DK3013350T3 (da) | 2013-06-25 | 2020-04-14 | Vaccinex Inc | Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser |
-
2017
- 2017-04-18 US US16/093,349 patent/US10884000B2/en active Active
- 2017-04-18 EP EP17722487.0A patent/EP3445786B1/en active Active
- 2017-04-18 BR BR112018070350A patent/BR112018070350A2/pt unknown
- 2017-04-18 EA EA201892313A patent/EA201892313A1/ru unknown
- 2017-04-18 WO PCT/FI2017/050286 patent/WO2017182706A1/en active Application Filing
- 2017-04-18 CA CA3020418A patent/CA3020418A1/en active Pending
- 2017-04-18 AU AU2017252344A patent/AU2017252344B2/en active Active
- 2017-04-18 JP JP2018554537A patent/JP7100588B2/ja active Active
- 2017-04-18 CN CN201780024373.4A patent/CN109153720B/zh active Active
- 2017-04-18 KR KR1020187028561A patent/KR102403660B1/ko active IP Right Grant
-
2022
- 2022-02-14 JP JP2022020859A patent/JP7302049B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019521312A5 (ja) | ||
Greening et al. | Bedside assessment of quadriceps muscle by ultrasound after admission for acute exacerbations of chronic respiratory disease | |
Rossi et al. | Identifying sarcopenia in acute care setting patients | |
Mao et al. | Analysis and comparison of the psychometric properties of three balance measures for stroke patients | |
JP2019503824A5 (ja) | ||
JP2012505012A5 (ja) | ||
Tibana et al. | Women with metabolic syndrome present different autonomic modulation and blood pressure response to an acute resistance exercise session compared with women without metabolic syndrome | |
WO2019157358A8 (en) | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases | |
JP2017505897A5 (ja) | ||
Pence et al. | Exercise speeds cutaneous wound healing in high-fat diet-induced obese mice. | |
Daniel et al. | Comparison of inter-canine and inter-molar width as an aid in gender determination: A preliminary study | |
JP2013094261A5 (ja) | ||
JP2020534125A5 (ja) | ||
Tak et al. | Association of inter-arm blood pressure difference with atherosclerosis in patients without cardiovascular diseases | |
Williams et al. | Research Methods: Translational Research in Geriatric Oncology | |
JP2018181352A5 (ja) | ||
Gurkan et al. | Yoga after coronary artery bypass graft surgery: its effect on anxiety and self-care agency | |
Öhman | Visualizing congestion with ultrasound: diagnostic and therapeutic implications | |
Sahoo et al. | Effect of exercise on nerve conduction study of Carpal tunnel syndrome patients | |
Teng et al. | Study on the responses of hypertensive patients to music | |
Xiang-Li et al. | Analysis of malaria situation and discussion of control strategy in Shandong Province Province, 2013 | |
TWM496455U (zh) | 血管彈性檢測裝置 | |
Karagiannis et al. | A61 LUNG FIBROSIS: ANIMAL MODELS II: Activin A And Follistatin Like-3 Levels In Bronchoalveolar Lavage Fluid Of Patients With Systemic Sclerosis Related Interstitial Lung Disease | |
RU2016117041A (ru) | Способ определения влияния лечебных или оздоровительных процедур на психофизиологическое состояние пациента (варианты) | |
Kim et al. | PRO160 COST ESTIMATION OF IMMUNOGLOBULIN RESCUE IN HOSPITALIZED PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): ANALYSIS OF A BRAZILIAN PRIVATE HEALTHCARE SYSTEM DATABASE |